Loading...
•
Dec 31, 2022
Theravance Q4 2022 Earnings Report
Announced strategic actions and reported financial results for the fourth quarter and full year 2022.
Key Takeaways
Theravance Biopharma announced its Q4 and full year 2022 financial results, along with strategic actions to sharpen focus and enhance shareholder value. The company is focused on driving YUPELRI’s growth, advancing the ampreloxetine pipeline, upsizing the capital return program to $325 million, and achieving non-GAAP profitability by the second half of the year.
Company is focused on enhancing shareholder value and delivering medicines to patients.
Company is positioned to drive YUPELRI’s growth and generate data from the PIFR-2 study in the second half of 2023.
Phase 3 study for ampreloxetine has been initiated and orphan drug designation is being pursued.
Capital return program is being upsized to $325 million and is expected to be completed by the end of the year.
Theravance
Theravance
Forward Guidance
Theravance Biopharma is focused on driving YUPELRI’s growth, advancing the ampreloxetine pipeline, upsizing the capital return program, and achieving non-GAAP profitability by the second half of the year.